Investing pharma fund healthcare thematic

Pharma and Healthcare mutual fund

From WebNotes, a public knowledge base. Last updated . Reading time ~6 min.

A Pharma and Healthcare mutual fund is a thematic equity scheme that invests at least 80 per cent of its corpus in pharmaceutical, healthcare, and life-sciences companies. The category sits within the SEBI sectoral and thematic framework. Pharma/healthcare is a popular thematic category among Indian retail investors, reflecting India’s position as a global pharma hub and the defensive characteristics of healthcare equity.

For Indian retail investors, pharma/healthcare mutual funds offer:

  • Defensive equity exposure: Less cyclical than industrials, banking.
  • Export-oriented growth: Indian pharma’s global export footprint.
  • Demographic tailwind: Aging populations driving healthcare demand.
  • Sectoral diversification: Pharma manufacturers + hospitals + diagnostics + medtech.

Major pharma/healthcare funds

  • ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D.) Fund.
  • SBI Healthcare Opportunities Fund.
  • Nippon India Pharma Fund.
  • DSP Healthcare Fund.
  • Aditya Birla Sun Life Pharma and Healthcare Fund.
  • Mirae Asset Healthcare Fund.
  • Tata India Pharma and Healthcare Fund.

Investment universe

Pharma/healthcare funds invest across:

  • Pharmaceutical manufacturers: Sun Pharma, Dr Reddy’s, Cipla, Lupin, Aurobindo, Torrent Pharma.
  • Hospitals: Apollo Hospitals, Max Healthcare, Fortis Healthcare.
  • Diagnostics: Dr Lal PathLabs, Metropolis Healthcare.
  • Medical equipment and devices: Various.
  • Specialty chemicals (related to pharma): Some allocation.
  • API manufacturers: Active Pharmaceutical Ingredient producers.

Defensive characteristics

Pharma and healthcare equity typically exhibits:

  • Lower correlation with overall market cycles.
  • Strong cash generation from established product portfolios.
  • Pricing power in some categories.
  • Demographic resilience to economic cycles.

These characteristics make the category attractive for defensive equity allocation.

Risks

  • Regulatory risk: USFDA inspections, drug pricing regulations.
  • Patent cliffs: Loss of exclusivity affecting revenues.
  • Generic competition: Pricing pressure.
  • Currency risk: Export-oriented earnings affected by INR.

Tax treatment

Pharma/healthcare funds are equity-oriented :

  • LTCG (>12 months): 12.5 per cent above Rs 1.25 lakh annual exemption under Section 112A .
  • STCG (≤12 months): 20 per cent under Section 111A .

Role in portfolios

Pharma/healthcare funds suit:

  • Defensive equity allocation: 5-10 per cent of equity portfolio.
  • Long-term demographic plays: Aging populations driving demand.
  • Tactical positioning: During specific pharma cycles.

See also

External references

References

  1. SEBI October 2017 categorisation circular.
  2. SEBI (Mutual Funds) Regulations 1996.
  3. AMFI scheme data on pharma/healthcare funds.

Related articles

  • NIFTY Pharma TRI

    The NIFTY Pharma TRI is the total-return variant of the NIFTY Pharma index, covering the 20 most liquid and large pharmaceutical and …

  • Banking and Financial Services mutual fund

    A Banking and Financial Services (BFSI) mutual fund is a thematic equity scheme that invests at least 80 per cent in banks, NBFCs, insurance …

  • Energy mutual fund

    An Energy mutual fund is a thematic equity scheme investing at least 80 per cent in oil, gas, power, renewables and energy-services …

  • FMCG and Consumption mutual fund

    An FMCG and Consumption mutual fund is a thematic equity scheme investing at least 80 per cent in fast-moving consumer goods and …

  • Infrastructure mutual fund

    An Infrastructure mutual fund is a thematic equity scheme investing at least 80 per cent in infrastructure, capital goods, construction, and …

  • Manufacturing mutual fund

    A Manufacturing mutual fund is a thematic equity scheme investing at least 80 per cent in manufacturing-themed companies including …

Reviewed and published by

WebNotes Editorial Team

The WebNotes Editorial Team covers Indian capital markets, payments infrastructure and retail investor procedures. Every article is fact-checked against primary sources, principally SEBI circulars and master directions, NPCI specifications and the official support documentation published by the intermediary in question. Drafts go through a second-pair-of-eyes review and a separate compliance read before publication, and revisions are tracked against the SEBI and NPCI rule changes referenced in the methodology section.

Last reviewed
Conflicts of interest
WebNotes is independent. No relationship with any broker, registrar or bank named in this article.